A biotech col­lect­ed $820 mil­lionin in­vestor com­mit­ments this month to take its Chi­na-sourced im­munol­o­gy drug on­to the pub­lic mar­kets. That would make it one...

Sum­mit Ther­a­peu­tics and Ake­so’s next-gen­er­a­tion can­cer drug ivonescimab earned an ap­proval in Chi­na last week for first-line pa­tients with cer­tain forms of lung can­cer. But it...

Eye­Point’s ex­per­i­men­tal eye treat­ment came up short of Eylea, the cur­rent go-to op­tion for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, ac­cord­ing to re­sults of a Phase 3...

As­traZeneca on Mon­day re­port­ed suc­cess­es in two late-stage tri­als in dif­fer­ent forms of lung can­cer — one with a two-drug com­bi­na­tion of Tagris­so and Or­pa­thys...